This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on August 1, 2000. The length of the article is 443 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Isis Pharmaceuticals' Genetrove division and the R.W. Johnson Pharmaceutical Research Institute initiate antisense target validation program.(Brief Article)
Publication:BIOTECH Patent News (Newsletter)
Date: August 1, 2000
Publisher: Biotech Patent News
Volume: 14 Issue: 8 Page: NA
Article Type: Brief Article
Distributed by Thomson Gale
Isis Pharmaceuticals' Genetrove division and the R.W. Johnson Pharmaceutical Research Institute initiate antisense target validation program.(Brief Article): An article from: BIOTECH Patent News
📄 Viewing lite version
Full site ›
Book Details
PublisherBiotech Patent News
ISBN / ASINB0008J11TM
ISBN-13978B0008J11T4
AvailabilityAvailable for download now
MarketplaceUnited States 🇺🇸